Asian Pac J Cancer Prev, 17 (5), 2485-2490

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common tumor and the third leading cause of cancer-related deaths, particularly in Africa, China, Korea, and other Asian nations. The liver is one of the most common sites of cancer in the world, hepatocellular carcinoma (HCC) predominating. Hepatitis C is a major risk factor and HCV is a rapid spreading virus which has become a problem globally, including in Pakistan. Interferon alpha therapy is used against HCV disease to regulate cell reproduction and to boost the immune system. In minute amounts interferon alpha is produced naturally by the immune system in HCV patients in response to hepatitis C virus and binds to receptors in the target cells and starts transcription of 20-30 genes due to which it develops an antiviral influence. Interferon is also administered artificially to overcome HCV disease and remove the biological effect of the virus from the infected site. The use of interferon or Peg-IFN plus Ribavirin treatment is also associated with adverse effects on body. For the current study, a convenient sample of 156 HCV positive patients of both males and females were taken. To collect blood CP and ALT, a reduction of level data and other important information were collected from the patients at regular intervals. Findings were 11.4 % in the red blood cells (RBC), 9.64 % in the total leukocyte count (WBC), 8.4 % in the hemoglobin levels (HB), 30.3 % in the platelet (Plt) count in both sexes. There was significant reduction in ALT levels due to Pegylated interferon plus ribavirin therapy. Hence strict haemotological monitoring of blood CP and ALT levels is necessary at regular intervals to reduce severe side effects which may lead to morbidity and mortality.

Keywords: HCV - pegylated interferon - ALT - ribavirin - heamtological parameters

Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients

Aziz Ur Rehman¹, Farhad Ali¹, Mashhood Ali¹, Ibrar Alam¹*, Abdul Wali Khan³

Abstract

The liver is one of the most common sites of cancer in the world, hepatocellular carcinoma (HCC) predominating. HCC is the sixth most common cancer and the third leading cause of cancer related death overall. Hepatitis C is a major risk factor and HCV is a rapid spreading virus which has become a problem globally, including in Pakistan. Interferon alpha therapy is used against HCV disease to regulate cell reproduction and to boost the immune system. In minute amounts interferon alpha is produced naturally by the immune system in HCV patients in response to hepatitis C virus and binds to receptors in the target cells and starts transcription of 20-30 genes due to which it develops an antiviral influence. Interferon is also administered artificially to overcome HCV disease and remove the biological effect of the virus from the infected site. The use of interferon or Peg-IFN plus Ribavirin treatment is also associated with adverse effects on body. For the current study, a convenient sample of 156 HCV positive patients of both males and females were taken. To collect blood CP and ALT, a reduction of level data and other important information were collected from the patients at regular intervals. Findings were 11.4 % in the red blood cells (RBC), 9.64 % in the total leukocyte count (WBC), 8.4 % in the hemoglobin levels (HB), 30.3 % in the platelet (Plt) count in both sexes. There was significant reduction in ALT levels due to Pegylated interferon plus ribavirin therapy. Hence strict haemotological monitoring of blood CP and ALT levels is necessary at regular intervals to reduce severe side effects which may lead to morbidity and mortality.

Keywords: HCV - pegylated interferon - ALT - ribavirin - heamtological parameters
are heart and renal failure, hypo and hyperthyroidism, disease of auto immune and visual loss (Trakroo et al., 2015). Other serious side effects of this combination therapy are suicidal tendency, depression and irritability. Dysfunctions of thyroid can also be caused by this therapy. One of the most serious and rare side effects is the neuro-retinitis. At this stage the therapy is dangerous and thus stopped completely (Pouresmaeeli et al., 2015).

Interferon therapy is also observed to suppress the bone marrow (Cuqueris et al., 2014). Anemia is a common side effect in patients by ribavirin dose which causes hemolysis is and leads to hemolytic anemia in taking combination pegylated interferon plus ribavirin treatment. At this point the treatment dosage needs to be adjusted or stopped altogether (Smolic et al., 2013).

In Pegylated interferon, pegylation works to extend its half-life and size for absorption. Interferon is removal from plasma is faster than pegylation of interferon, however due to pegylation it works better. Hepatitis C patients having genotype 1 requires therapy for longer time because of lower response but the response result is higher when HCV patients are given therapy of pegylated interferon with ribavirin. The time duration of the therapy based on genotypes in HCV patients with genotype-2 and genotype-3 is 6 months, whereas the samples of HCV genotype-1 requires 1 year (National Institutes of Health, 2002; Pawlotsky et al., 1999). In Pakistan, Peg-INF is recommended for therapy of Hepatitis C patients by National Institute of Health (NIH). Interferon therapy of 3 MIU is given to the HCV positive patients three times a week for duration of 24 weeks (Alam et al., 2013).

Peg-INF plus Ribavirin therapy has been proved to have three folds efficiency to the HCV virological response (Masood et al., 2010). In most cases platelet count decrease due to therapy of pegylated interferon/ribavirin but in severe condition (Hezode et al., 2013) may leads to bleeding, at this stage the therapy needs to be stopped. IFN alpha therapy suppresses bone marrow which leads to cytopenia. In combination, IFN plus ribavirin therapy may causes anemia due to hemolysis. Ribavirin also cause anemia, because RBV enters in red blood cells and due to phosphorylation it is converted into active state, and that phosphorylation reduces adenosine triphosphate (ATP) which leads to ribavirin triphosphosphate (Maasoumy et al., 2013). Ribavirin triphosphosphate accumulates sixty fold than its normal concentration in plasma and it is difficult for erythrocytes to metabolize and results in damaging membrane oxidation and thus causing hemolysis. Erythropoiesis suppressed when regulation of erythrocyte receptor accumulates thus causing anemia. Haematological toxicities may be improved dose reduction however it carries the risk of an additional treatment response (Elshahawi et al., 2015).

The aim of the present study was to identify the biochemical and hematological parameters of HCV patients taking the therapy of pegylated interferon plus ribavirin treatment with the following objectives, to investigate the effect of Peg-INF plus RBN therapy on ALT and on blood composition in chronically infected HCV patients.

Materials and Methods

The sample collection and study design was conducted at Shaheed Zulfiqar Ali Bhutto Medical University (PIMS Hospital) Islamabad Pakistan from December 2014 to June 2015. Convenience sample of 156 HCV patients of both male and female were included in the study. The exclusion of patients from the study was made on the basis of alcoholic consumption or drug abuse, less controlled psychiatric disease, HBS Ag positive and liver disease at the final stage. Socio-demographic information i.e. age, sex, marital status, location, education, marital status, location and approach of patient knowledge with disease procedure like signs, causes, and symptoms etc. filled according to project questionnaire. Blood sampling from the HCV patients were carried out at the duration of one month up to the 3rd month of the treatment.

i). To confirm Hepatitis C viral RNA and Anti-sera; ii). Information about twenty four hours dietary recall; iii). Haematological and biochemical tests; iv). Statistical analysis

Confirmation of Hepatitis C Viral RNA And Antisera

Initially all the subjects were screened for anti-HCV antibodies by Immuno-Chromatographic Tests (ICT) and every HCV positive sample was tested twice then followed for anti-HCV antibodies by ELISA technique (Biokit, S.A, Barcelona-Spain) according to the instructions given by the manufacturer followed by RNA extraction and PCR confirmation of positive samples.

HCV RNA was extracted from 200 μl sample taken from serum by using Ana-gen RNA extraction Kit (Ana-gen, USA) followed by RT-PCR (reverse transcription PCR), by using of enzyme reverse transcriptase M-MLV (Fermentas, USA). The cDNA was prepared by their present primers, then amplified cDNA subjected for amplification of two round PCR. For PCR amplification initial denaturation was carried out at 95°C for 2 minutes followed by denaturation at 94°C by 45 seconds, annealing temperature of 54°C for 45 seconds and then extension at 72°C performed in a thermal cycler (Eppendorf, Germany) for one minutes. Inner primers of different set for the 2nd round PCR were used with the same conditions, however for first round amplification the annealing temperature was raised to 62°C.

The total products of PCR in first and second rounds were then visualized by agarose gel of 1.8% which was prepared in the TBE buffer of 0.5% and was stained with (10 mg/ml) ethedium bromide used as florescent dye. Alpha quant (Alpha Innotech) was used for gels photographing. For DNA size marker100-bp (Gibco BRL) DNA ladder was used.

### Table 1. Age Groups of the HCV Positive Patients

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Gender</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Below 25 years</td>
<td>25</td>
<td>28</td>
</tr>
<tr>
<td>26-35 years</td>
<td>27</td>
<td>26</td>
</tr>
<tr>
<td>36 &amp; Above</td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>TOTAL</td>
<td>78</td>
<td>78</td>
</tr>
</tbody>
</table>
Haemotological And Biochemical Tests

HCV positive patient’s blood was collected and serum was separated from the blood samples by centrifugation technique. After that different hematological and biochemical results were carried out.

SGPT/ALT was also tested by Roche/Hitachi 902 which is a fully automatic analyzer and function on basis of spectrophotometer. Automatically the sample and reagents were mixed in a cuvette and SGPT/ALT was calculated at 340 nm wavelength. By automatic analyzer (Model XS-1000i) blood complete pictures was calculated. HCV patients WBC level, SGPT level, RBC level, HB count and platelet count were calculated at one month interval.

Statistical Analysis

The data generated was statistically analyzed by computer software program JMP. SAS (Version 7.0, SAS, USA).

Results

The study was carried out to analysis the changes in blood composition i.e. ALT, WBC, RBC, HB and Platelets count due to therapy of Peg-IFN plus ribavirin in HCV chronic patients. In the present study 156 samples were included. Both sexes were participated in the study comprising of 78 male and 78 female patients and were divided into three groups. Different blood levels were observed in chronic HCV subjects for 3 months interval (Table 1).

Changes in Red Blood Cells

The changes in the mean blood composition of RBC levels in both sexes of chronic HCV patients taking pegylated interferon plus ribavin therapy are shown in Figure 1. From the statistical analysis significant reduction (p ≤ 0.001) was observed in RBC levels with a series of three months therapy. Mean changes in the RBC levels at the initial stage of treatment in males patients were 4.28 ± 1.45 (106/µL) and changes in the levels of RBC in females were 4.14 ± 1.29 (106/µL). According to baseline data of red blood cells levels in both male and female HCV chronic patients no significant difference was observed. Patients receiving Peg-IFN plus RBV therapy led to reduction of 11.04% red blood in both sexes having chronic HCV disease. In male patients 11.1% decrease and 11.0% decrease in females was observed (Figure 1).

Changes in White Blood Cells

The changes in the blood composition mean WBC levels in both sexes of chronic HCV patients taking pegylated interferon plus ribavirin therapy are showed in Figure 2. From the statistical analysis a significant reduction (p ≤ 0.001) in WBC levels was observed with a series of three months therapy. In males changes in the levels of WBC (8324.36 ± 2757.72 (/µL) at the baseline vs. 7521.15 ± 1.81 at month 3) and changes in the levels of WBC in females were 8291.33 ± 2718.48 (/µL) was observed. According to baseline data of white blood cells in both male and female HCV chronic patients there was no significant difference. Receiving therapy of Peg-IFN plus RBV led to reduction of 10% in white blood cells in both sexes having chronic HCV disease. Thus in male patients 9.9% decrease and 10.1% decrease in females were observed (fig:2).

Changes in Hemoglobin

The changes in the blood composition mean HB count

![Graph](image1)

![Graph](image2)

![Graph](image3)
in both sexes of chronic HCV patients taking pegylated interferon plus ribavirin therapy are shown in Figure 3. HB count was significantly reduced (p ≤ 0.001) with a series of three months therapy. Mean changes in the levels of WBC at the initial stage of treatment in males patients were 13.35 ± 0.14 (g/dL) and changes in the levels of HB count in females were 12.55 ± 2.99 (g/dL). According to baseline data of hemoglobin count in both male and female HCV chronic patients no significant difference was observed. Receiving therapy of Peg-IFN plus RBV led to reduction of 8.1% of HB in both sexes having chronic HCV disease. Thus in male patients 8.25% decrease and 7.96% decrease in females were observed (fig:3).

Changes in Platelet Counts

The changes in the blood composition mean platelets count in both sexes of chronic HCV patients taking pegylated interferon plus ribavirin therapy are shown in Figure 4. From the statistical analysis significant reduction (p ≤ 0.001) in HB count with a series of three months therapy was observed. Mean changes in the levels of WBC at the initial stage of treatment in males patients were 208994.8 ± 49497.5 (/µL) and changes in the levels of PLT count in females were 201144.16 ± 484814.7 (/µL). According to baseline data of platelets count in both male and female HCV chronic patients there were no significant differences. Receiving therapy of Peg-IFN plus RBV led to reduction of 30.6% of PLT in both sexes having chronic HCV disease. Thus in male patients 30.5% decrease and 30.5% decrease in females were observed (fig:4).

Discussion

The major parameter that was studied in the research was changes in the blood composition in response to Hepatitis C infection. The changes in the blood composition were highly significant. For assessing blood composition changes, Red blood cells (RBC), Leucocyte Count (WBC), Hemoglobin (HB), Platelet (Plt) count were measured.

The changes were studied for three months interval during the pegylated interferon plus ribavirin therapy. Comparisons were also recorded between the changes after treatment data and baseline readings. The suitable treatment of chronic hepatitis C is the therapy of Peg-IFN alpha and RBN (Sugimoto et al., 2015).

The currently peg-interferon plus ribavirin therapy denoted as gold standard of therapy that improves responses for all genotypes (National Institutes of Health 2002; Hunyady et al., 2011). Peg-IFN alpha and ribavirin was administered to the patients for 6 months. Serum alanine aminotransferase (ALT) activity and variables were most commonly measured because it assess to hepatic disease (Nadeem et al., 2007). Due to large amount of ALT secretion into the blood caused liver injury.

In the present study all the patients (100%) receiving Combination Peg-IFN therapy showed uniform reduction in ALT levels and gradual normalization of the ALT levels. The uniform reduction in the ALT levels was found approximately same in the patients of both sexes. Similar findings have also been found where no relationship was established between male and female and the response to therapy (Nadeem et al., 2007).

The total reduction in ALT levels in the present study is 29.62%. A 37.9% reduction (p=0.001) in ALT levels due to therapy is reported (Alam I et al., 2014). He also reported that 86% patients responded positively to combination Peg-IFN therapy, and 97% in the patients showed normalization at 24 weeks of treatment. In the present study the response of the ALT to the therapy was positive.

In the present study all the HCV positive subjects (male and female) were taking Peg-IFN plus ribavirin therapy. Pegylated Interferon suppresses bone marrow as a result by thrombocytopenia and neutropenia. The TLC significantly (p=0.001) decreased in males and females. According to Iliescu, (2010) leukocytes (WBC) reduced 30-40% during therapy. In the reported study significant reduction in TLC of 1.11x10³/µL (p=0.001) (Ghaniet al., 2009). The hematological disorders were reported during Peg-IFN and ribavirin therapy in chronic HCV patients.

RBC reduced by 21.13% which can lead to anemia. RBC is responsible for carrying oxygen and nutrients to the whole body. Its decrease in the blood can cause anemia. Low levels of RBC during interferon treatment, was also observed (Aspinall et al., 2004). In their study mostly HCV patients received pegylated interferon/ribavirin combination treatment experience anemia in mild to moderate stage. In reported study the side effects in 11241 HCV positive patients treated with Peg-IFN alpha therapy. About 5 patients died due to liver failure because of interferon treatment. In eight positive patients adverse effects was life threatening. Two attempted suicide because of depression and six patients were reported with the bone marrow suppression. No hepatic diseases were observed in 131 positive patients, out of 131, the 71 patients having disease of thyroid, ten diabetes mellitus patients, five having auto-immune systemic disease, 5 with impotence, about 14 patients effected with the disease of dermatologic, ten with psychosis, seven with heart disease, four have seizures, three with neuropathy and two hemolytic anemia patients also included. The conclusion of this study was the adverse effects of interferon may be life threatening (Fattovich et al., 1996).

Total leukocyte count (TLC) reduced by 1.30x10⁹/L at
Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients

DOI:http://dx.doi.org/10.7314/APJCP.2016.17.5.2485

Aspinall R, Pockros P (2004). The management of side effects during interferon therapy may be lifesaving.


recurrence of hepatocellular carcinoma. Oncology, 2, 42-46.